Menu
Back to Journals » Journal of Asthma and Allergy » Volume 14
Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Authors Menzella F , Lusuardi M, Galeone C, Taddei S, Zucchi L
Received 24 June 2021
Accepted for publication 24 June 2021
Published 29 June 2021 Volume 2021:14 Pages 753—754
Menzella F, Lusuardi M, Galeone C, Taddei S, Zucchi L. J Asthma Allergy. 2015;8:105–114.
Page 107, Table 1, Efficacy column, Asthma row, the text “Mepolizumab reduces peripheral blood eosinophilia, percentage of bone marrow eosinophils, airway eosinophils, and rate of exacerbations in almost all RCTs. Improvements in FEV 1 were found in only two studies13,36” should read “Mepolizumab reduces peripheral blood eosinophilia, percentage of bone marrow eosinophils, airway eosinophils, and rate of exacerbations in almost all RCTs”.
The authors apologize for this error.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.